We randomly assigned 208 patients , of whom 5 ( 1 rhEPO and 4 placebo ) withdrew consent and 3 ( placebo ) became ineligible ( retinal thrombosis , respiratory insufficiency , SOD1 mutation ) before receiving treatment ; 103 receiving rhEPO and 97 placebo were eligible for analysis .